ABN Amro Investment Solutions Has $21.81 Million Stock Position in Gilead Sciences, Inc. $GILD

ABN Amro Investment Solutions increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 263.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 177,649 shares of the biopharmaceutical company’s stock after buying an additional 128,716 shares during the period. ABN Amro Investment Solutions’ holdings in Gilead Sciences were worth $21,805,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Brighton Jones LLC raised its holdings in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $215,000. Sivia Capital Partners LLC grew its position in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC grew its position in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after purchasing an additional 12,705 shares during the period. Finally, Diversify Advisory Services LLC grew its position in shares of Gilead Sciences by 18.6% in the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after purchasing an additional 674 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.1%

Shares of Gilead Sciences stock opened at $130.69 on Thursday. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29. The stock has a market cap of $162.26 billion, a P/E ratio of 17.81 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The business’s 50 day moving average is $136.86 and its 200-day moving average is $133.57.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on GILD shares. Deutsche Bank Aktiengesellschaft boosted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Daiwa Securities Group reduced their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday. The Goldman Sachs Group upped their price target on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Argus upped their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Finally, Royal Bank Of Canada reduced their price target on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating for the company in a research report on Friday, May 8th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $156.93.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Maxim Group upgraded Gilead Sciences (GILD) from hold to buy and set a $165 price target, signaling meaningful upside from current levels. Benzinga report on Maxim Group upgrade
• Positive Sentiment: Gilead announced a quarterly dividend of $0.82 per share, reinforcing its appeal as a cash-generating, income-producing biotech with a 2.5% annualized yield.
• Neutral Sentiment: Gilead launched a new $3 billion senior notes offering, which boosts balance-sheet flexibility but also adds to debt financing activity that investors may watch closely. TipRanks article on senior notes
• Neutral Sentiment: Zacks noted that GILD is drawing unusual investor attention, but the item did not include a fresh fundamental catalyst. Zacks trending stock article
• Negative Sentiment: Daiwa Securities trimmed its price target on Gilead to $150 from $161, suggesting some moderation in analyst expectations despite maintaining an outperform rating. MarketScreener report on Daiwa target cut
• Negative Sentiment: Recent insider selling by senior executives, including the CFO, may create a small overhang for sentiment, even though the trades were pre-planned. InsiderTrades report on CFO sale

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,000 shares of company stock worth $8,523,570 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.